Clinical Trial Update: DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial (DAREON-Lung-1) evaluating Obrixtamig plus atezolizumab with carboplatin and etoposide versus standard chemotherapy in advanced small cell lung ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• Obrixtamig (BI 764532)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 3 | Status: RECRUITING